International Association for the Study of Lung Cancer

Support for this project from Eli Lilly and Company is gratefully acknowledged.

Lilly | Oncology

Scroll

The 1970's

70s Intro Video

  1. 1972

    Lymph node mapping introduced

    1972 Fig
  2. 1972

    Radiotherapy included in combined modality treatment for SCLC and NSCLC

    1972 Fig
  3. 1972

    First International Workshop for Therapy of Lung Cancer, Virginia, USA

    1972 Fig
  4. 1973

    Sublobular resection adequate for limited-stage lung cancer

    1974 Fig
  5. 1974

    ACTH research identified SCLC as an ectopic hormone-producing tumor

    1974 Fig
  6. 1974

    First IASLC Board of Directors convenes

    1974 Fig
  7. 1974

    First data-driven revision of TNM classification of lung cancer

    1974 Fig
  8. Mid 70

    Chemotherapeutic agents show low response in NSCLC but higher in SCLC

    Mid 70s Fig
  9. 1975

    Fluorescence bronchoscopy as improved diagnostic tool

    1975 Fig
  10. 1975

    First issue of IASLC News, Lawrence Broder, MD, Editor

    1975 Fig
  11. 1976

    Histological types of lung cancer determined through cytology

    1976 Fig
  12. 1976

    First report of immune therapy using BCG in early-stage lung cancer

    1976 Fig
  13. 1976

    Association between smoking dose and time relationship with lung cancer mortality; link between asbestos and lung cancer found

    1976 Fig
  14. 1978

    Mediastinoscopy used to select surgical procedure options

    1978 Fig
  15. 1978

    1st WCLC, in Hilton Head, USA

    1975 Fig
  16. 1978

    Chest computed tomography introduced for staging and radiotherapy planning

    1978 Fig
  17. 1979

    Cisplatin approved by FDA, it and etoposide show high activity in SCLC

    1976 Fig
  18. 1979

    Early impact analysis undertaken of reduction in 1950s cigarette tar and nicotine

    1976 Fig

The 1980's

70s Intro Video

  1. 1980

    2nd WCLC, in Copenhagen, Denmark

    1980 Fig
  2. 1980

    60 Gy most effective dose in NSCLC

    1980 Fig
  3. 1980

    IASLC Pathology Panel formed

    1980 Fig
  4. 1981

    IASLC Pathology Committee proposes revision of WHO classification of SCLC

    1981 Fig
  5. 1981

    First IASLC workshop, on SCLC, at Ashford Castle, Ireland

    1981 Fig
  6. 1982

    3rd WCLC, in Tokyo, Japan

    1981 Fig
  7. 1983

    Impact of secondhand smoke on lung cancer demonstrated

    1983 Fig
  8. 1983

    Etoposide, methotrexate and parapatin approved by FDA

    1983 Fig
  9. 1983

    Mediastinal lymph node staging less invasive with flexible transbronchial needle aspiration

    1983 Fig
  10. 1985

    4th WCLC, in Toronto, Canada

    1985 Fig
  11. 1985

    More than 100 SCLC cell lines established

    1985 Fig
  12. 1985

    IASLC journal Lung Cancer, Heine H. Hansen, MD, Editor

    1985 Fig
  13. 1986

    Increase in adenocarcinoma histologic type of lung cancer

    1986 Fig
  14. 1986

    Adjuvant chemotherapy has survival impact after NSCLC carcinoma resection

    1986 Fig
  15. 1986

    New staging system for lung cancer proposed

    1986 Fig
  16. 1987

    Thoracic radiotherapy plus chemotherapy improves locoregional control in SCLC

    1987 Fig
  17. 1987

    Chemotherapy established as care standard for good PS SCLC patients, despite toxicity

    1987 Fig
  18. 1987

    5th WCLC, in Interlaken, Switzerland

    1988 Fig
  19. 1989

    Quality-of-life assessment tools validated

    1989 Fig
  20. 1989

    Paraplatin approved by FDA for NSCLC

    1989 Fig
  21. 1989

    Chest x-ray and sputum screening for lung cancer not recommended

    1989 Fig

The 1990's

90s Intro Video

  1. 90s

    Adjuvant chemotherapy improves survival in NSCLC

    90s Fig
  2. 1991

    Quality of life identified as an independent prognostic factor

    1991 Fig
  3. 1991

    6th WCLC, in Melbourne, Australia

    1991 Fig
  4. 1991

    First IASLC Executive Director, Heine H. Hansen, MD

    1991 Fig
  5. 1992

    ‘Basaloid carcinoma’ proposed as new NSCLC subtype

    1992 Fig
  6. 1992

    Three-drug combinations shown to not be superior two-drug in SCLC

    1992 Fig
  7. 1992

    EGFR identified as target for prevention and treatment of lung cancer

    1992 Fig
  8. 1992

    Chemotherapy plus radiotherapy increases survival vs radiotherapy alone in NSCLC

    1992 Fig
  9. 1993

    Lung cancer and cardiopulmonary deaths positively associated with air pollution

    1991 Fig
  10. 1994

    7th WCLC, in Colorado, USA

    1994 Fig
  11. 1994

    IASLC Tobacco Policy established

    1994 Fig
  12. 1995

    PET established as component of pre-operative staging prior to thoracotomy

    1995 Fig
  13. 1997

    Revision of TNM staging include division of stages I and II as IA, IB, IIA, and IIB

    1997 Fig
  14. 1997

    8th WCLC, in Dublin, Ireland

    1997 Fig
  15. 1997

    "Grunenwald’s approach" identified for surgical treatment of difficult apical lung cancer

    1997 Fig

The 2000's

70s Intro Video

  1. 2000

    Increase in lung cancer deaths among women due to smoking demonstrated

    2000 Fig
  2. 2000

    9th WCLC, in Tokyo, Japan

    2000 Fig
  3. 2000

    Neoadjuvant chemotherapy demonstrates survival results

    2000 Fig
  4. 2001

    "Chemotherapy doublet efficacy plateau" demonstrated

    2001 Fig
  5. 2002

    Zoledronic acid approved by FDA

    2002 Fig
  6. 2003

    Gefitinib for NSCLC with EGFR mutations by FDA;, distribution later limited

    2003 Fig
  7. 2003

    Dr. Paul Bunn becomes Executive Director

    2003 Fig
  8. 2003

    10th WCLC, in British Columbia, Canada

    2003 Fig
  9. 2004

    Discovery that certain EGFR mutations associated with response to EGFT TKIs

    2004 Fig
  10. 2004

    Four-dimensional CT useful for tumor motion and localization

    2004 Fig
  11. 2004

    Pemetrexed with cisplatin for malignant pleural mesothelioma approved by FDA

    2004 Fig
  12. 2004

    Prostacyclins shown to have chemopreventive effects in animal models

    2004 Fig
  13. 2004

    Erlotinib for NSCLC approved by FDA

    2004 Fig
  14. 2004

    FDG-PET plus CT shown to improve target volume definition for NSCLC RT planning

    2004 Fig
  15. 2005

    11th WCLC, in Barcelona, Spain

    2005 Fig
  16. 2005

    Paradigm established for histology confirmation before chemo- and targeted therapy

    2005 Fig
  17. 2006

    Bevacizumab approved by FDA for first-line treatment of NSCLC

    2006 Fig
  18. 2006

    IASLC journal, Journal of Thoracic Oncology launches, James Jett, MD, Editor

    2006 Fig
  19. 2006

    IASLC Textbook of Prevention and Detection of Early Lung Cancer, Fred R. Hirsch, MD, PhD, Editor

    2006 Fig
  20. 2006

    Diagnostic tools include EBUS and electromagnetic navigation bronchoscopy

    2006 Fig
  21. 2007

    IASLC Staging Committee collects 100,000 cases to determine prognosis with TNM variables

    2007 Fig
  22. 2007

    12th WCLC, in Seoul, Korea

    2007 Fig
  23. 2007

    Topotecan approved by FDA for SCLC

    2007 Fig
  24. 2007

    Transforming EMLA4-ALK fusion gene identified in NSCLC

    2007 Fig
  25. 2008

    Genetic variants identified that confer risk for developing lung cancer

    2008 Fig
  26. 2008

    Cell-cell interactions that regulate immune responses better defined

    2008 Fig
  27. 2008

    Pemetrexed approved in combination for locally advanced or metastatic NSCLC

    2008 Fig
  28. 2009

    Pemetrexed approved by FDA as maintenance treatment for NSCLC

    2009 Fig
  29. 2009

    13th WCLC, in San Francisco, USA

    2009 Fig
  30. 2009

    IASLC Staging Manual in Thoracic Oncology, Peter Goldstraw, FRCS, Executive Editor

    2000 Fig

The 2010's

Closure Intro Video

  1. 2010

    Targetable genetic abnormalities identified in up to 60% of pulmonary adenocarcinomas

    2010 Fig
  2. 2010

    Erlotinib for maintenance treatment for NSCLC approved by FDA

    2010 Fig
  3. 2010

    Denosumab for bone metastases approved by FDA

    2010 Fig
  4. 2010

    Contribution of supportive and palliative lung cancer care to survival and treatment compliance demonstrated

    2010 Fig
  5. 2010

    Use of biomarkers established for identifying optimal therapy, age of personalized medicine

    2010 Fig
  6. 2011

    Crizotinib approved by FDA for NSCLC patients who are ALK-positive

    2011 Fig
  7. 2011

    14th WCLC, in Amsterdam, the Netherlands

    2011 Fig
  8. 2012

    Nab-paclitaxel in combination with carboplatin for NSCLC approved by FDA

    2012 Fig
  9. 2012

    Clinical activity of targeting the PD-1/PD-L1 pathway in lung cancer demonstrated

    2012 Fig
  10. 2013

    CAP/IASLC/AMP Molecular Testing Guideline published

    2013 Fig
  11. 2013

    Dr. Fred R. Hirsch becomes CEO

    2013 Fig
  12. 2013

    Erlotinib for metastatic NSCLC with EGFR-activating mutations approved by FDA

    2013 Fig
  13. 2013

    Afatinib for NSCLC with EGFR-activating mutations approved by FDA

    2013 Fig
  14. 2013

    15th WCLC, in Sydney, Australia

    2013 Fig

Support for this project from Eli Lilly and Company is gratefully acknowledged.

Lilly | Oncology

Back to Top